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Sickle cell disease (SCD) is one of the commonest severe inherited disorders, but specific treatments are lacking and the
pathophysiology remains unclear. Aﬀected individuals account for well over 250,000 births yearly, mostly in the Tropics, the
USA, and the Caribbean, also in Northern Europe as well. Incidence in the UK amounts to around 12–15,000 individuals and
is increasing, with approximately 300 SCD babies born each year as well as with arrival of new immigrants. About two thirds of
SCD patients are homozygous HbSS individuals. Patients heterozygous for HbS and HbC (HbSC) constitute about a third of SCD
cases, making this the second most common form of SCD, with approximately 80,000 births per year worldwide. Disease in these
patients shows diﬀerences from that in homozygous HbSS individuals. Their red blood cells (RBCs), containing approximately
equal amounts of HbS and HbC, are also likely to show diﬀerences in properties which may contribute to disease outcome.
Nevertheless, little is known about the behaviour of RBCs from HbSC heterozygotes. This paper reviews what is known about
SCD in HbSC individuals and will compare the properties of their RBCs with those from homozygous HbSS patients. Important
areas of similarity and potential diﬀerences will be emphasised.
1. Introduction
Like homozygous HbSS individuals, individuals heterozy-
gous for HbS and HbC (HbSCs) suﬀer from sickle cell
disease (SCD) [1–6]. The condition in HbSC patients (here
called HbSC disease cf. HbSS disease in homozygotes) not
only has some overlap with that seen in HbSS patients,
but also has distinctive laboratory and clinical features
identifying it as a separate entity [6–8]. Although HbSC
disease is one of the commonest significant genetic dis-
eases worldwide, it is comparatively neglected with very
few laboratory or clinical studies addressing the condition
directly. Thus, whilst extensive research has been carried
out on understanding SCD in HbSS patients, little relates
specifically to the pathogenesis in HbSC patients. In clinical
trials of potential novel therapies for SCD, HbSC patients are
often specifically excluded. Furthermore, most clinical and
laboratory features of HbSC disease have been inferred from
studies of HbSS, which may not be appropriate. This paper
addresses the pathophysiological diﬀerences shown by SCD
in HbSS and HbSC patients and the diversity in their clinical
complications. Particular reference is paid to the transport
abnormalities of the RBC membrane.
2. Genotypic Variants of SCD
All SCD patients have the abnormal haemoglobin HbS in
their red cells instead of the normal adult HbA [9–12]. HbS
results from a single base mutation in codon 6 of the β-
globin gene which causes a single amino acid substitution
in position β6 (glutamic acid → valine, with net loss of
one negative charge). Homozygous HbSS patients have two
copies of the altered gene. The mutation arose in West
Africa, where the high prevalence of HbS appears to be due
to selection pressure conferred by a relative resistance to
malaria. Malaria resistance has also increased the prevalence
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of a second abnormal Hb, HbC, which like HbS represents
one of the most prevalent forms of abnormal human Hb.
HbC also has a single mutation/amino acid change at the
same position in β-Hb, but with lysine replacing glutamic
acid (hence net loss of two negative charges). These changes
in protein charge may alter how the diﬀerent Hbs interact
and modulate transporter function at the RBC membrane
[13]. The charge diﬀerences are also used for electrophoretic
tests for abnormal Hb, although care must be exercised to
exclude certain non-SCD haemoglobinopathies which may
mimic HbSC. Homozygous HbCC individuals show few
disease symptoms apart from a mild haemolytic anaemia
[6]. Heterozygotes of HbA with either HbS or HbC are also
largely asymptomatic. Coinheritance of HbS and HbC to
produce HbSC heterozygotes, however, results in a clinically
significant disease similar, but not identical, to that in HbSS
individuals [6–8]. Although globally HbSC heterozygotes
represent about a third of SCD cases, their distribution
is by no means uniform. HbC appears to have originated
in Burkina Faso [6] where HbSC cases may outnumber
those of HbSS. In other areas, such as the Middle East
and India, HbSC cases are rare. In this context, it is worth
pointing out that estimates of the frequency of diﬀerent
haemoglobinopathies are likely to be inexact, relying on
outdated or incorrect information [14].
3. HbSC Disease as a Unique Clinical Entity
All cases of SCD, including those of HbSC disease, are
characterised by shortened red cell life span and chronic
anaemia, together with recurrent episodes of more acute
vaso-occlusion, tissue ischaemia, and increased mortality
[12]. Aﬀected individuals have a poor quality of life with
numerous complications, for example, pain, cerebrovascular
disease (strokes), renal and pulmonary damage, leg ulcers,
and priapism [2]. An important feature of SCD is that
the clinical scenario is notably heterogeneous—patients
may present with mild forms of the disease which rarely
require medical intervention or alternatively with more
severe complications warranting frequent hospitalisation
and aggressive management. Presumably modifier genes
and/or environmental factors are significant, but although
this area is now receiving considerable attention, it remains
poorly understood at present [15–17].
In most cases, HbSC disease is clinically milder than
HbSS disease and the various complications of SCD usually
occur less often or later in life [8]. For example, leg ulcers and
other chronic vascular manifestations occur infrequently.
Loss of splenic function is relatively delayed, preserving red
cell scavenging and thereby possibly aﬀecting disease com-
plications. Nevertheless, HbSC disease still has a significant
impact on patients who show haemolytic anaemia, organ
failures (stroke, renal failure, chronic lung disease.), and
increased mortality (with a median survival of 60 years
for males in USA) [15, 18]. Pregnant women sometimes
develop complications having been hitherto asymptomatic
[19]. Complications also occur in children with the risk
of stroke in childhood being about 100 times greater than
that in the general population [18]. Furthermore, in HbSC
heterozygotes, some of the serious complications of SCD
(such as osteonecrosis) are as common as for HbSS patients
and some (e.g., proliferative sickle retinopathy and possibly
acute chest syndrome) occur more frequently [8]. This is also
apparent for some central auditory and vestibular problems
[19].
Additionally, HbSC is haematologically distinct from
HbSS, with higher Hb levels (but lower levels of HbF),
lower rates of haemolysis and lower white cell counts [8].
Some of these features are well illustrated in clinical and
haematological observations on patients from our clinics
(see [20, Table 1]). These distinctive features imply that
individuals with HbSC disease should be treated as a discrete
subset of SCD patients.
Currently there is very little specific information on the
pathophysiology and management of HbSC disease, with
much being inferred from studies of HbSS patients. Diﬀer-
ences in pathogenesis between HbSC and HbSS disease are
expected, however. Understanding them will be important in
the management of HbSC patients and may also contribute
to a better appreciation of the condition in homozygous
individuals.
4. Pathogenesis of SCD
Although the underlying molecular defect of SCD is long
established, how HbS results in the clinical complications
remains poorly understood. The chronic anaemia and acute
ischaemic episodes both are associated with altered rheology
and increased adhesiveness of both RBCs and vascular
endothelium [21]. RBCs are more fragile and more readily
scavenged from the circulation, contributing to the chronic
anaemia, whilst microvascular occlusion is also encouraged
causing the acute ischaemic events characteristic of SCD.
Intravascular haemolysis is observed and the consequent
release of Hb to circulate freely in plasma contributes
to the vasculopathy, probably by scavenging nitric oxide
(NO) and causing a functional deficiency of that molecule
[22, 23]. Some authors divide the disease complications
of SCD into two broad categories, with sequelae caused
either predominantly by altered RBC rheology and elevated
blood viscosity (e.g., pain, osteonecrosis, and acute chest
syndrome) or by intravascular haemolysis and NO scaveng-
ing (e.g., pulmonary hypertension, stroke, priapism, and leg
ulceration) [24–26]. In any event, polymerisation of HbS
on deoxygenation is central to anaemia, vaso-occlusion, and
haemolysis—although complete deoxygenation may not be
needed, especially in the case of hyperdense RBCs with
high cell [Hb], such as some of those found in HbSC
individuals. Formation of long rods of HbS distorts RBC
shape, reduces deformability, and increases viscosity, thus
compromising vascular red cell rheology [27]. Other key
events in the pathogenesis have been identified. First, red
cell volume is critically important [28]. The increased
cation permeability of HbS-containing red cells results in
solute loss with water following osmotically. Consequently,
[HbS] increases. As the rate of HbS polymerisation upon
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Figure 1: Schematic diagram of the main transport pathways activated in red blood cells (RBCs) from sickle cell patients. In RBCs from
homozygous HbSS individuals, high cation permeability is accounted for by three main pathways [28, 37]. Under oxygenated conditions,
the KCl cotransporter (KCC) is highly active. It is overexpressed in HbSS cells compared to HbAA ones and does not become quiescent as
RBCs mature. It is stimulated further by low pH (reduction in extracelluar pH from 7.4 to 7). Under deoxygenated conditions, KCC remains
active—again unlike the situation in HbAA RBCs [40]. In addition, two other pathways are observed. The deoxygenation-induced cation
conductance (or Psickle) is activated as HbS polymerises. It mediates entry of Ca2+. Elevation in intracellular Ca2+ then leads to activation
of the third pathway, the Ca2+-activated K+ channel, or Gardos channel. These three pathways result in solute loss, cell shrinkage and
dehydration, and consequent increase in [HbS]. They thereby contribute to pathogenesis of sickle cell disease. They are also likely to be
involved in solute loss from RBCs of patients heterozygous for HbS and HbC (HbSC genotype), though details are lacking and diﬀerences
in their behaviour compared to that in HbSS cells are expected.
deoxygenation is proportional to a very high power of [HbS],
a small reduction in cell volume and hence increase in [HbS]
markedly encourages HbS polymerisation [27]. Second, red
cell stickiness is also increased [21, 29–31]. This results,
at least in part, from exposure of phosphatidylserine (PS)
on the outer bilayer of the membrane [32]. Exposed PS
is prothrombotic and increases adherence of red cells to
macrophages and endothelium, contributing to chronic
anaemia, haemolysis, and vaso-occlusion [33]. Again, the
cause of PS exposure is not clear, but sickling-induced Ca2+
entry may play an important role [34]. Third, SCD represents
an inflammatory state with raised levels of cytokines, chronic
elevation of leukocyte counts, shortened leukocyte half-life,
and abnormal activation of granulocytes, monocytes, and
endothelium [35, 36]. The resulting cytokine stimulation of
endothelial cells increases their adhesiveness to sickle RBCs
[35, 36]. How these various changes interact to produce the
symptoms of SCD represents a major research challenge. In
addition, the extent to which these various mechanisms are
involved in disease pathogenesis would be expected to diﬀer
between HbSS homozygotes and HbSC heterozygotes. For
example, reduced intravascular haemolysis in the latter may
ameliorate NO scavenging.
5. Altered Membrane Transport in
Homozygous HbSS Cells
Increased membrane permeability of HbS-containing red
cells contributes to SCD pathogenesis by promoting Ca2+
entry, KCl loss with water following osmotically, and
hence RBC dehydration [28, 34, 37]. In HbSS cells, the
involvement of three pathways has been proposed: the
KCl cotransporter (KCC), the deoxygenation-induced cation
conductance (or Psickle), and the Ca2+-activated K+ channel
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Figure 2: Eﬀect of oxygen tension on the activity of KCl cotransport
(KCC) or Psickle in red blood cells (RBCs) from normal indi-
viduals or patients with sickle cell disease. The activity of each
transport pathway is normalised—to the value in oxygenated cells
(150 mmHg O2) for KCC activity and for that in deoxygenated
RBCs (0 mmHg) in the case of Psickle—and given as a percentage.
Solid circles give KCC activity in RBCs from normal HbAA
individuals; open symbols give KCC activity (open circles) or Psickle
activity (open triangles) in RBCs from sickle cell patients (HbSS
homozygotes). In these experiments, total magnitude of KCC
activity was about 10-fold greater in RBCs from HbSS individuals
compared with HbAA ones. Note how the deoxygenation-induced
KCC activity and activation of Psickle follow a similar dependence on
O2 tension. Data taken from [67].
4 Anemia
(or Gardos channel, KCNN4) [28]. These three systems are
illustrated schematically in Figure 1.
The first of these, KCC (likely KCC1 and KCC3 isoforms),
is more active and abnormally regulated in HbSS cells [38–
40]. Mean activity is enhanced >10-fold in unstimulated cells
with several stimuli increasing activity further. In normal
RBCs, cell swelling is an important trigger of KCC activity
[41]. For HbSS cells, however, intracellular pH is probably
the most important stimulus in vivo, with KCC activity
reaching a peak at about pH 7 [38, 42]. The transporter also
responds to O2 tension [43]. In normal red cells, high levels
of O2 are required for KCC activity, with the transporter
becoming inactivated at low O2. By contrast, in HbSS cells,
the transporter remains active during full deoxygenation,
thereby allowing it to respond to low pH in hypoxic areas
(like active muscle beds) [40] (Figures 1 and 2). KCC is
regulated by phosphorylation, through cascades of conjugate
protein kinases and phosphatases [44], with diﬀerences
apparent in HbSS cells compared with HbAA ones, but
at present these are poorly defined. The relative deficiency
of intracellular Mg2+ in HbSS cells [45, 46] probably acts
to increase KCC activity by altering the activity of these
regulatory enzymes.
The second pathway, Psickle, is apparently unique to
HbS-containing red cells [28, 34]. It is activated to a
variable extent by deoxygenation, HbS polymerisation, and
shape change [47, 48] (Figures 1 and 2). Psickle has the
characteristics of a nonspecific cation channel [34]. An anion
permeability is controversial, whilst, more recently, it has
been proposed as permeable under certain conditions to
nonelectrolytes [49]. The main eﬀect of Psickle is probably
the increased Ca2+ entry [49, 50] and possibly the Mg2+
loss [45]. Raised intracellular Ca2+ has several roles which
include phospholipid scrambling [51]. It will also activate
the third pathway responsible for HbS cell dehydration,
the Gardos channel [52] (Figures 1 and 3). The Gardos
channel is then capable of mediating very rapid eﬄux
of K+ with Cl− following for electroneutrality and water
osmotically.
These mechanisms cause solute loss and HbSS cell
shrinkage. Episodes may be short lived and produce only
modest degrees of solute loss. But they may occur repeatedly
during the lifetime of the RBCs, often during deoxygenation-
induced sickling events. Accordingly, HbSS cells show an
increase in MCHC of a few percent compared to normal
red cells (c.34 g·dL−1 cf. 33 in HbAA cells, density approx
1.085 g·mL−1), but importantly there is a large range
about this mean with many dense cells (>1.095 g·ml−1,
MCHC c.38 g·dl−1), some of which are exceedingly dense
(1.125 g·ml−1, c.50 g·dl−1) [53]. A significant feature of
HbSS RBCs is their marked heterogeneity, with certain sub-
populations possibly more important in pathogenesis [28].
The densest HbSS cells are mainly older ones, presumably
following repeated episodes of solute loss [54]. Reticulocytes
are mostly low density (c.26 g·dl−1), as they are in normal
individuals [55]. However, there is a small fraction of young,
dense HbSS cells, the so-called fast-track reticulocytes, which
become rapidly dehydrated on deoxygenation while still
young [28, 56].
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Figure 3: Components of K+ transport pathways and sickling in
red blood cells (RBCs) from sickle cell disease patients heterozygous
for HbS and HbC (HbSC genotype). K+ influxes are given as flux
units [mmol·(l cells·h)−1] measured at 5 mM [K+]o and numbers
of sickled cells as a percentage of total RBCs in fully oxygenated
(150 mmHg O2) or deoxygenated (0 mmHg) conditions. Although
this technique measures a K+ influx, because of the high K+ content
of RBCs, net solute movement through the transport systems will
be outwards. KCl cotransport activity was calculated as the Cl−-
dependent K+ influx, Gardos channel activity as the clotrimazole
(5 μM)-sensitive K+ influx, and Psickle as the Cl−-independent K+
influx (Cl− substituted with NO3−). Sickling, Psickle, and Gardos
channel activation occurs in deoxygenated conditions—as for HbSS
RBCs—but KCC activity is low when O2 is removed (as in RBCs
from HbAA cells). Data taken from [64].
6. Altered Properties of HbSC Cells
RBCs from HbSC patients also show K+ loss, raised MCHC
and haemolytic anaemia with reticulocytosis [5, 57–59].
The properties of HbSC RBCs, however, diﬀer in important
respects from those of HbSS cells. In HbSC cells, K+ loss
and dehydration are markedly more pronounced [58, 59].
MCHC is particularly high, at about 37 g·dl−1 (cf. 33 g·dl−1
in HbAA individuals; 33-34 g·dl−1 for the reversibly sickled
fraction of HbSS patients) [57, 58]. Whilst most reticulocytes
from normal HbAA and HbSS are characteristically low
density (26 g·dl−1), HbSC reticulocytes are mainly high
density (MCHC c.34 g·dl−1) [5, 58]. Usually older RBCs
are denser; however the monotonic decrease in reticulocyte
count with increasing cell density observed for red cells from
HbSS patients (as well as HbAA and HbAS individuals)
does not occur in HbSC patients [5, 60]. Instead, HbSC
reticulocytes are fairly evenly distributed across the diﬀerent
RBC densities [5], or perhaps even more concentrated in
the denser fractions [60]. This has been taken as evidence
that a significant proportion of young HbSC cells begin their
lives with a high density [5], rather than undergoing a more
gradual dehydration observed in HbSS cells upon repeat
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Figure 4: Conductance of red blood cells (RBCs) from sickle cell patients heterozygous for HbS and HbC (HbSC genotype). (a), (b)
Representative whole-cell recordings from (a) oxygenated and (b) deoxygenated RBCs. (c) Mean whole-cell currents + S.E.M., n = 5.
Test potentials from −80 to +80 mV were applied for 300 ms in 10 mV increments from a holding potential of −10 mV. Measurements were
made using Na+-containing bath and pipette solutions. Data taken from [20]. See [66] for experimental details. The conductance of RBCs
from HbSC patients is high and increases further on deoxygenation.
episodes of sickling. In this respect, perhaps the majority of
HbSC reticulocytes behave like the “fast-track” reticulocytes
of HbSS patients [56]—cells which dehydrate rapidly on
leaving the bone marrow—but this remains to be established.
It also raises the question as to what constitutes RBCs in
the less dense HbSC fractions. Can shrunken HbSC cells
regain lost solute and increase their volume? If so, what is
the mechanism and what are transport systems involved?
As heterozygotes, HbSC cells contain both HbS and HbC,
in approximately equal amounts (i.e., 50%). This contrasts
with the lower HbS content (c.40%) found in sickle trait
HbAS cells [5]. Crystals of HbC are sometimes present
in oxygenated RBCs. In contrast to HbS polymers, these
deposits are lost on deoxygenation [60]. Because of the high
HbS content and polymerisation, HbSC cells also show a
deoxygenation-induced sickling shape change. In this case,
however, rather than the HbSS sickles and holly leaf forms,
deoxygenated HbSC cells show multifolded shapes such as
“pita breads” and “tricorns” [60], perhaps because of the
high surface area to volume ratio subsequent to their more
marked dehydration. How HbS and HbC interact has also
received some attention. Using diﬀerent Hb mixtures, a
direct interaction between the two Hbs appears to only
slightly enhance HbS polymerisation. Much more important
in HbSC disease is RBC dehydration and consequently the
high MCHC [5, 61, 62]. High MCHC and lower levels of
HbF may have an eﬀect on the extent and kinetics of HbS
polymerisation whilst concurrent Hb mutations (such as β-
thalassaemia) may also play a significant role.
It is therefore critical to understand fully the mechanisms
by which these RBCs shrink, but our understanding of the
mechanisms involved remains uncertain. Oxygenated HbSC
cells have elevated KCC activity that is stimulated by low pH
and swelling [13, 60]. Cytoplasmic protein concentration has
been suggested as the “volume” sensor of RBCs [63]. It is
therefore intriguing to speculate that high KCC activity in
oxygenated HbSC cells may result from the presence of HbC
crystals which would lower the total concentration of soluble
Hb, as occurs in swollen RBCs. In eﬀect, the cells “think” that
they are swollen and so activate mechanisms to lose solutes
and water, namely, KCC. On the other hand, deoxygenated
HbSC cells also show increased K+ eﬄux, to an extent
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apparently greater than that observed in deoxygenated HbSS
cells [58]. Which pathway mediates the flux in deoxygenated
conditions, however, has not been established. If Psickle is
involved, given the lower [HbS] of HbSC cells, it is not
clear why it should be activated to a greater extent than in
HbSS cells. KCC and the Gardos channel represent obvious
alternative pathways.
A number of manoeuvres which reduce reticulocyte
density may provide evidence for the transport pathways
involved in their dehydration. Both Cl− removal and
deoxygenation shift HbSC reticulocytes to lower densities,
consistent with solute retention following inhibition of
KCC [60]. Hypotonic swelling of HbSC cells also reduces
the deoxygenation-induced K+ loss [58], perhaps through
reduction in [HbS] removing a Psickle-like element of K+ flux.
In preliminary studies, we have observed high KCC
activity in oxygenated unfractionated HbSC cells, which was
almost completely inhibited on deoxygenation [64]. Thus,
KCC in HbSC cells behaved like that in HbSS cells at
high O2 tension and like that in HbAA cells when tension
was reduced [64] (Figure 3). We also found activation of
a deoxygenation-induced Cl−-independent K+ flux [64],
a deoxygenation-induced nonelectrolyte permeability [65]
and a deoxygenation-induced rise in K+ conductance in
patch-clamp experiments [66] (Figure 4), namely, a Psickle-
like permeability, together with activation of the Gardos
channel. In this context, it is interesting that HbC has a
higher aﬃnity for the RBC membrane than either HbA
or HbS [59] leading to an early suggestion that HbSC
interaction is involved in modulating RBC permeability.
It is apparent, however, that our understanding of the
permeability of HbSC cells requires further investigation.
7. Conclusion: The Importance of Cell
Dehydration in HbSC Disease
Understanding dehydration is particularly relevant for HbSC
cells. The solubility of deoxygenated HbS is about 17 g·dl−1
compared to 70 g·dl−1 for HbA. As HbS represents only
about half the total Hbs in HbSC cells, a relatively small
decrease in MCHC (from an RBC total of 37 to 33 g·dl−1)
will prevent HbS polymerisation [61] while retaining the
functionally important discocyte morphology. As HbS con-
stitutes about half the Hbs in these RBCs, this would mean
a fall in [HbS] from 18.5 to 16.5. In comparison, in HbSS
cells, a reduction of MCHC to <25 g·dl−1 is required, by
which time RBCs will be spherocytic, and cell swelling per
se will adversely aﬀect rheology [58]. Notwithstanding their
relevance to dehydration and sickling, the permeability of
HbSC cells has not been well studied nor compared in
detail with that of HbSS cells. Several areas require more
careful investigation. The interaction between diﬀerent Hbs,
membrane target sites regulating permeability, the transport
pathways involved, the role of cell density, oxygenation,
volume, and pH presents a complex pattern of modalities
controlling solute content and hence cell density and MCHC.
Control by phosphorylation remains mainly unexplored.
The challenge ahead lies to define the most important
stimuli and how they interact to determine cell volume. A
major therapeutic goal is the ability to prevent HbSC cell
dehydration or to promote rehydration.
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Here we term red cells from HbSS patients as HbSS cells,
those from HbSC individuals as HbSC cells.
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